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Chromatin-remodeling enzymes in control of Schwann
cell development, maintenance and plasticity
Claire Jacob
Gene regulation is essential for cellular differentiation and
plasticity. Schwann cells (SCs), the myelinating glia of the
peripheral nervous system (PNS), develop from neural crest
cells to mature myelinating SCs and can at early developmental
stage differentiate into various cell types. After a PNS lesion,
SCs can also convert into repair cells that guide and stimulate
axonal regrowth, and remyelinate regenerated axons. What
controls their development and versatile nature? Several recent
studies highlight the key roles of chromatin modiﬁers in these
processes, allowing SCs to regulate their gene expression
proﬁle and thereby acquire or change their identity and quickly
react to their environment.
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Introduction
SCs originate from neural crest cells that also give rise to
other cell types including sensory neurons, chondrocytes,
melanocytes, smooth-muscle cells [1,2]. After speciﬁca-
tion in SC precursors, the lineage further differentiates
into immature SCs that encircle bundles of axons of
different calibers. Next, big caliber axons are sorted in
a one-to-one relationship with SCs by a process called
radial sorting which leads to the promyelinating stage.
The last step of maturation is the myelination process
where SCs build a thick myelin sheath rich in lipids
around axons (Figure 1). Meanwhile, small caliber axons
remain in bundles associated with non-myelinating SCs
and persist as Remak bundles in adult nerves [3,4].
Myelin provides axonal insulation and fast conduction
of electric signals along axons; its formation and mainte-
nance are thus critical for neuronal functions. By contrast,
myelin is detrimental for axonal regrowth after lesion,
because it contains growth inhibitory proteins [5]. How-
ever, SCs react quickly to an axonal lesion by dediffer-
entiating, digesting their own myelin — a process called
myelinophagy [6] — and converting into repair cells [7,8]
that foster axonal regrowth and guide axons back to their
former target [9,10]. SCs then remyelinate regenerated
axons (Figure 2). This remarkable SC plasticity allows the
PNS to functionally regenerate after lesion.
This review is focused on the mechanisms of SC devel-
opment, maintenance and plasticity after lesion con-
trolled by chromatin-remodeling enzymes. Chromatin
remodeling regulates the accessibility of genes for the
transcriptional machinery, and thereby gene activation
and repression. Changes of chromatin architecture are
controlled by ATP-dependent nucleosome remodeling
and by covalent modiﬁcations, either on DNA by meth-
ylation or on histones by various post-translational mod-
iﬁcations including acetylation, methylation, phosphory-
lation, ubiquitination, SUMOylation, ADP-ribosylation.
Although our knowledge on these mechanisms is still very
sparse, recent ﬁndings on the functions of chromatin-
remodeling enzymes have signiﬁcantly contributed to a
better understanding of their critical functions in SCs.
Chromatin-remodeling factors controlling SC
development, maintenance and plasticity after
lesion
Nucleosome-remodeling complexes, DNA methylation/
demethylation, histone acetylation/deacetylation and
methylation/demethylation enzymes have been shown
to hold key functions in SCs (Figures 1 and 2).
Nucleosome-remodeling complexes
Nucleosome-remodeling complexes use ATP to destabi-
lize the interaction between DNA and histones. This
local chromatin destabilization results in nucleosome
sliding and repositioning that can also lead to adjacent
nucleosome ejection or insertion. These changes of chro-
matin structure modify DNA accessibility, and can lead to
either transcriptional activation or repression. Nucleo-
some-remodeling complexes are classiﬁed into different
families, based on their composition and activity: SWI/
SNF, ISWI, INO80/SWR1 and NuRD complexes [11].
Among those, the SWI/SNF and the NuRD complexes
are known to regulate aspects of SC development and
plasticity after lesion (Figures 1 and 2). Two subtypes
BAF and PBAF of SWI/SNF complexes are known; they
owe their enzymatic activity to their ATPase subunit
BRM or BrG1 [12]. The NuRD complex comprises
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CHD3 or CHD4 as ATPase subunit, and has in addition
deacetylase activity by the recruitment of HDAC1 and
HDAC2 [13].
DNA methyltransferases (DNMTs)
DNMTs transfer a methyl group from a methyl donor,
generally S-adenosylmethionine (SAMe) to the carbon
5 of cytosines located within CpG dinucleotides [14].
Most CpGs in mammalian genomes are maintained
methylated across generations by DNMT1. By contrast,
CpG islands in promoters and enhancers often remain
unmethylated through active DNMTs exclusion. This
usually requires recruitment of a transcription factor and
other partners such as histone H3 lysine 4 (H3K4) methyl-
transferases (HMTs), a TET dioxygenase and a thymi-
dine DNA glycosylase that erase/prevent methylation.
Promoter silencing can however occur through de novo
methylation at CpG islands by DNMT3A or DNMT3B,
Figure 1
Current Opinion in Neurobiology
Chromatin-remodeling enzymes and associated mechanisms regulating SC development and maintenance. Activating mechanisms are depicted
above and inactivating mechanisms underneath SC stages. The table lists mouse mutants and their phenotypes used to identify these
mechanisms.
Figure 2
Current Opinion in Neurobiology
Chromatin-remodeling mechanisms regulating SC plasticity after lesion. Activating mechanisms are depicted above and inactivating mechanisms
underneath regeneration stages. The table lists mouse mutants and their phenotypes used to identify these mechanisms.
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and is usually preceded by repressive H3K9 methylation
marks. Interestingly, in the case of very low availability of
methyl donor, DNMT3A/B cannot methylate CpGs, but
in contrast have been reported to actively participate in
DNA demethylation [15].
Histone acetylation and deacetylation enzymes
Histone acetyltransferases (HATs) add acetyl groups to
lysines of histone tails, which loosens the attraction
between histones and DNA and results in chromatin
decompaction that facilitates the access for the transcrip-
tional machinery. By contrast, HDACs remove these
acetyl groups, which leads to a more condensed chromatin
that restricts DNA access [16]. HATs are thus commonly
thought to act as transcriptional co-activators, whereas
HDACs as transcriptional co-repressors. However, sev-
eral studies have shown that HDACs can also participate
in transcriptional activation [17–19]. HATs and HDACs
cannot bind DNA directly and thus need a DNA-binding
partner to modify histones. In addition, these enzymes
can acetylate and deacetylate and thereby control the
activity of non-histone targets including several transcrip-
tion factors [20]; they are thus very powerful transcrip-
tional regulators. Eighteen known mammalian HDACs
are subdivided into four classes, based on their structure
[21]. HDAC1 and HDAC2, two highly homologous class I
HDACs that can usually compensate each other’s func-
tions, have been extensively studied in SCs.
Histone methylation and demethylation enzymes
HMTs catalyze the addition of methyl groups to target
residues, whereas histone demethylases (HDMs) remove
these methyl groups. Histones can be methylated on the
three basic residues K, arginine (R) and histidine (His),
although His methylation is rare. Activating methylation
marks are located on H3K4, H3K36, H3K79, H3R17 and
H3R26, and repressive methylation marks on H3K9,
H3K27, H4K20 and H3R8, whereas methylation of
H3R2 and H4R3 leads either to transcriptional activation
or repression, depending on the exact location of the
methyl group. There are several families of HMTs and
K HDMs, but the existence of R HDMs is not clear [22].
Functions of chromatin-remodeling enzymes
in SC development and maintenance of PNS
integrity
SC development from speciﬁcation of the lineage to
terminal differentiation into myelinating cells and main-
tenance of myelination require transcriptional activation
of genes that induce lineage differentiation and acquisi-
tion and maintenance of cell stage identity. HDAC1 and
HDAC2 (HDAC1/2) and the BAF complex hold major
functions in these processes. For differentiation to pro-
ceed, inactivating inhibitory mechanisms of SC differen-
tiation is also necessary. In addition, preventing over-
myelination is required for stable myelination and
optimal nerve conduction. The NuRD complex as well
as DNA and histone methylation regulate these mecha-
nisms. Current knowledge on this topic is discussed
below and summarized in Figure 1.
HDAC1/2 control SC lineage speciﬁcation
The transcription factor Sox10 is essential for SC lineage
speciﬁcation and the entire SC developmental process
[23]. However, Sox10 is expressed in all neural crest cells.
Thus, additional mechanisms direct Sox10-dependent
speciﬁcation into the SC lineage. Indeed, ablation of
HDAC1/2 in neural crest cells by crossing Hdac1/2 ﬂoxed
mice with mice expressing the Cre recombinase (Cre)
under control of the Wnt1 promoter (Wnt1-Cre) prevents
peripheral glia speciﬁcation [24]. We show that HDAC1/2
and Sox10 interact to activate the promoter of the early
lineage marker Myelin protein zero (P0 [25]) and of Pax3,
another key transcription factor for SC speciﬁcation
[26,27]. In turn, Pax3 and Sox10 activate the Sox10
MCS4 enhancer (also called U3 [28,29]) to maintain high
levels of Sox10, which induces expression of P0 and Fatty
acid binding protein 7 (Fabp7), another early peripheral glia
marker [30].
HDAC1/2 regulate radial sorting, SC survival, induction
and maintenance of myelination
HDAC1/2 have also essential functions at later develop-
mental stages and in the maintenance of integrity in adult
nerves. Ablation of HDAC1/2 in SC precursors (by cross-
ing Hdac1/2 ﬂoxed mice with mice expressing Cre under
control of the Dhh promoter) leads to radial sorting delay
and virtual absence of myelin, followed by massive SC
apoptosis [31]. We showed that HDAC1/2 maintain SC
survival by limiting active-beta-catenin (ABC) levels and
that they interact with Sox10 to activate the Sox10 and P0
promoters and the Krox20 MSE (myelinating SC element
[32]), a critical enhancer for expression of the major
transcription factor of SC myelination Krox20 [33]. In
adult SCs, ablation of HDAC1/2 (using the tamoxifen-
inducible CreERT2 under control of the P0 promoter)
leads to disruption of paranodal and nodal structures,
followed by moderate demyelination due to 50% loss
of P0 expression, presumably caused by impairment of
Sox10-mediated activation of the P0 promoter [34]. Chen
et al. [35] also showed that HDAC1/2 interact with the
transcription factor NFkB to activate the Sox10 promoter
in SCs during developmental myelination. However in
vivo NFkB inactivation leads to minor effects on myeli-
nation [36], therefore this mechanism may have a minor
control over in vivo myelination.
The BAF complex ATPase BrG1 is required for radial
sorting and myelination
Ablation of BrG1 in SC precursors (using ﬂoxed Brg1 and
Dhh-Cre mouse lines) prevents radial sorting and myelina-
tion [37,38]. Limpert and colleagues (2013) show that BrG1
interacts with NFkB to activate the Sox10 promoter and
suggest that this mechanism controls BrG1-dependent SC
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myelination [37]. However, given the minor effect of in
vivo NFkB inactivation on myelination [36], BrG1 inter-
action with NFkB is likely to have minor functions on SC
myelination. Furthermore, while Sox10 levels are moder-
ately [37] or not [38] affected in the absence of BrG1 in SCs,
Oct6, Krox20 and P0 are virtually absent. Indeed, the BAF
complex is recruited by Sox10 to the Oct6 SCE (SC
enhancer [39]), the Krox20 MSE and the P0 promoter to
induce Oct6, Krox20 and P0 expression [38–40], and
thereby controls the myelination process.
The NuRD complex regulates radial sorting and
myelination
As mentioned earlier, Krox20 is a major transcription
factor of SC myelination, which is absolutely required
for the activation of myelin genes and the production of
peripheral myelin [33]. Interestingly, Krox20 can also act
as a transcriptional repressor. Indeed, Krox20 can interact
with the transcriptional repressors NAB1/2, which recruit
the NuRD complex to silence expression of inhibitors of
myelination including Id2, Id4 and cJun at a late myelina-
tion stage [41–43]. Consistently, ablation of the NuRD
complex ATPase CHD4 in immature SCs (using ﬂoxed
Chd4 and P0-Cre mouse lines) leads to increased expres-
sion of inhibitors of myelination and to hypomyelination
[43]. Ablation of CHD4 also leads to delayed radial
sorting [43]. At this earlier developmental stage, the
NuRD complex may allow radial sorting by silencing
the transcription of Sox2, Hey2 and Ednrb [44,45],
other inhibitors of SC differentiation, together with the
transcription factor Zeb2. Indeed, Zeb2 has been shown
to recruit the NuRD complex in SCs [44] and ablation
of Zeb2 in SC precursors (using ﬂoxed Zeb2 and Dhh-Cre
mouse lines) leads to upregulation of Sox2, Hey2 and
Ednrb and prevents radial sorting and myelination
[44,45]. However, ablation of Zeb2 results in a more
severe phenotype as compared to ablation of CHD4 [43],
suggesting that Zeb2 acts also through CHD4-indepen-
dent mechanisms. Alternatively, the different levels of
phenotype severity between Zeb2 and Chd4 mutant mice
could be due to the different Cre mouse lines used to
generate these mutants.
DNA demethylation adjusts myelin thickness
DNA demethylation of selected genes appears necessary
for appropriate developmental myelination. Indeed,
DNA demethylation at promoters and enhancers of mye-
lin genes (Mbp, Pmp22, Prx, Cnp), transcriptional regula-
tors of myelination (Lgi4, Nab1, Nfatc1) and lipid metab-
olism genes (Scap, Srebf1, Hmgcr, Mvk, Pmvk, Dgat1, Lipe,
Scd1, Abca2 and Elovl7) correlates with upregulation of
these genes during myelination [46]. Simultaneously,
expression of DNMTs decreases and expression of
Gadd45a (growth arrest and DNA damage 45a), Gadd45b,
and Apobec1 (apolipoprotein B mRNA editing enzyme
catalytic subunit 1), which promote DNA demethylation
[47], increases [46]. The principal methyl donor SAMe
is converted into S-adenosylhomocysteine and N-methyl-
glycine by Glycine N-methyltransferase (GNMT, [48]).
Ablation of GNMT impairs this conversion and thus
increases the availability of SAMe, which results in a thin
myelin phenotype in constitutive Gnmt mutant mice
[46,48]. These data provide further evidence that
DNA demethylation of myelin-related genes allows
SCs to build myelin sheaths of appropriate thickness
during development.
Involvement of repressive histone methylation marks in
regulating myelination
Other repressive mechanisms mediated by H3K27me3
marks on gene promoters have been reported during the
myelination process. Ness and colleagues (2016) identify
Nuc-ErbB3, a nuclear variant of ErbB3, as a DNA-bind-
ing protein that promotes H3K27me3 at gene promoters
presumably by activating the HMT EZH2. This study
reports that loss of Nuc-ErbB3 (constitutive mouse
mutant) leads to developmental hypermyelination [49].
Consistently, ablation of the PRC2 subunit Eed in imma-
ture SCs (using ﬂoxed Eed and P0-Cre mouse lines), that
leads to inactivation of the PRC2 complex (mediating
H3K27me3 through its HMT EZH2), results in hyper-
myelination in adults [50]. This is due to impaired
repression of Igfbp2 that maintains the activation of
Akt-dependent myelination [50]. However, no defect
in developmental myelination occurs in Eed mutants
[50]. A third study conducted in SC cultures proposes
that loss of EZH2 leads in contrast to the inhibition of the
myelination process through impaired inactivation of
p75kip2 transcription that promotes expression of the
inhibitor of myelination Hes5 [51]. These inconsistencies
need to be resolved with additional in vivo studies.
Functions of chromatin-remodeling enzymes
in SCs after lesion
Regenerative properties of the PNS after lesion are to a
large extent due to the plasticity of SCs that ﬁrst de-
differentiate and convert into repair cells in response to
injury to foster and guide axonal regrowth, and second re-
differentiate to remyelinate regenerated axons [3,5,7,10].
These different key steps of the regeneration process
involve the dynamic regulation of many genes and thus
the timed action of several transcription factors, which are
known to promote either SC de-differentiation or re-
differentiation after lesion. In comparison, our knowledge
on the functions of chromatin-remodeling enzymes and
their coordinated action with transcription factors after
lesion is just emerging with recently published studies
that are discussed below and illustrated in Figure 2.
HATs, HDACs, HMTs and HDMs control the conversion
into repair cells, their cell cycle and functions after
lesion
In adult nerves, injury-induced genes are silenced by the
PRC2 complex, which adds repressive H3K27me3 marks
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at their promoter [52]. Upon injury, these genes are de-
repressed by H3K27 demethylation and activated by
H3K4 methylation at promoter regions and by H3K27
acetylation at enhancers, the latter correlating with
recruitment of the transcription factor cJun [52,53], a
major inducer of SC conversion into repair cells [54]. This
mechanism allows the expression of injury-induced genes
including Shh and the neurotrophic factor Gdnf [52], and
thus promotes axonal regrowth after lesion.
De-differentiated SCs re-enter the cell cycle after injury.
To prevent SC overproliferation that could lead to tumor
formation, the Arf/Ink4 locus is de-repressed by the HDM
JMJD3 that demethylates H3K27 at the promoter of
p19Arf and p16Ink4a and potentially also at the p15Ink4b
promoter. These tumor-supressor proteins then inacti-
vate SC proliferation [55].
Even though the conversion of SCs into repair cells after
lesion is efﬁcient, it is interesting to point out that this
process is not optimal and can be improved. Indeed,
shortly after injury, HDAC2 is upregulated in SCs and
mediates the assembly of a protein complex with the two
H3K9 HDMs KDM3A and JMJD2C and the transcrip-
tion factor Sox10, which is recruited to the Oct6 SCE to
demethylate H3K9 and induce Oct6 transcription. In turn,
Oct6 slows down the upregulation of cJun [56]. Consis-
tently, ablation of HDAC1/2 in adult SCs (using the
tamoxifen-inducible P0-CreERT2 mouse line) or a
short-term treatment with the HDAC1/2 inhibitor Moce-
tinostat delays Oct6 upregulation after lesion and leads to
higher and earlier cJun upregulation, earlier conversion
into repair cells and faster axonal regrowth [56].
HDAC1/2 and the NuRD complex promote remyelination
after lesion
At the remyelination stage, the same protein complex
assembled by HDAC2 after lesion (described above) is
recruited to the Krox20 MSE to demethylate H3K9 and
activate Krox20 transcription [56]. Krox20 then induces
remyelination. In the absence of HDAC1/2 in adult SCs,
Krox20 expression is strongly reduced. This results in
impaired remyelination [56], indicating that HDAC1/2
are necessary for the remyelination process after lesion.
Of note, a short-term HDAC1/2 inhibitor treatment after
lesion (during the 3 days following lesion) does not
interfere with the remyelination process, but leads to
faster functional recovery due to faster and more efﬁcient
axonal regeneration, as mentioned above [56], thereby
identifying a novel treatment to accelerate PNS regener-
ation after lesion.
To enable remyelination after lesion, it is also necessary
to downregulate inhibitors of myelination such as Sox2,
Hey2 and Id2. Similar to its function in developing SCs,
the transcription factor Zeb2 represses the promoter of
these genes in conjunction with the NuRD complex to
silence their expression and thereby allow remyelination
[44,45].
Conclusion
In summary, each step of SC development, the mainte-
nance of integrity in adult nerves and the regeneration
process after a PNS lesion are controlled by chromatin-
remodeling enzymes that either modify histones, DNA or
remodel nucleosomes. The recent studies discussed in
this review show that several chromatin-remodeling
enzymes or events act in sync to regulate one cellular
process. It appears also increasingly obvious that chroma-
tin-remodeling enzymes are often targeted to a speciﬁc
set of genes through their interaction with transcription
factors, and thereby act as co-factors of these transcription
factors to enable the regulation of their target genes.
Although recent ﬁndings have improved our understand-
ing of chromatin-remodeling enzymes functions in SC
development, maintenance and plasticity, a lot more
work — preferentially carried out in vivo — is necessary
to fully understand their functions and mechanisms of
action, resolve inconsistencies, and potentially use and
control them in disease contexts. In particular, it will be of
major importance in future studies to analyze the coordi-
nated action of different types of chromatin-remodeling
enzymes, and elucidate their mode of activation and
recruitment to speciﬁc target genes. Mass spectrometry
combined with chromatin immunoprecipitation analyses
will certainly reveal instrumental to identify dynamic
protein complex formation and recruitment to speciﬁc
loci depending on the developmental or regeneration
stage.
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